The global biopharmaceutical contract manufacturing market size is projected to grow by USD 9 十亿来自 2022 到 2028, 复合年增长率为 8.9 百分, 根据 Gen Consulting 公司的一份新报告.

该报告提供了有关当前全球市场情况的深入分析和见解, latest trends and drivers into global biopharmaceutical contract manufacturing market. 它提供了对市场规模等各种细节的独家见解, 主要趋势, 竞争格局, 增长率和细分市场. This study also provides an analysis of the impact of the COVID-19 crisis on the biopharmaceutical contract manufacturing industry.

该行业报告提供了全球市场的市场估计和预测, 接下来是对产品的详细分析, service, source, 组织规模, 和地区. The global market for biopharmaceutical contract manufacturing can be segmented by product: 生物制剂, biosimilars. 在 2021, the biologics segment made up the largest share of revenue generated by the biopharmaceutical contract manufacturing market. Biopharmaceutical contract manufacturing market is further segmented by service: analytical and QC studies, fill and finish operations, 包装, process development. Based on source, the biopharmaceutical contract manufacturing market is segmented into: mammalian, microbial-based biologics/non-mammalian. The mammalian segment is estimated to account for the largest share of the global biopharmaceutical contract manufacturing market. 根据组织规模, the biopharmaceutical contract manufacturing market also can be divided into: 大型企业, small and medium-sized enterprises (中小企业). The large enterprises segment held the largest share of the global biopharmaceutical contract manufacturing market in 2021 预计在预测期内将持有其份额. Biopharmaceutical contract manufacturing market by region is categorized into: 北美, 欧洲, 亚太, 世界其他地区.

副产品:
– 生物制剂
– biosimilars

按服务:
– analytical and QC studies
– fill and finish operations
– 包装
– process development

按来源:
– mammalian
– microbial-based biologics/non-mammalian

按组织规模:
– 大型企业
– small and medium-sized enterprises (中小企业)

按地区:
– 北美
– 欧洲
– 亚太
– 世界其他地区

The biologics market is further segmented into monoclonal antibodies (mAbs), 重组蛋白, 疫苗, 其他的. 在这些当中, the mAbs segment was accounted for the highest revenue generator in 2021.

The report explores the recent developments and profiles of key vendors in the Global Biopharmaceutical Contract Manufacturing Market, including AbbVie, 公司, Ajinomoto Co. 公司, Boehringer Ingelheim Biopharmaceuticals GmbH, 康泰伦特, 公司, Emergent BioSolutions Inc., FUJIFILM Holdings Corporation, 龙沙集团公司, 默克公司, 辉瑞公司, Samsung Biologics Co., 有限公司, Serum Institute Of India Pvt. 有限公司, 赛默飞世尔科技, 公司, WuXi Biologics, 公司, 除其他外.
*索取免费样品以获得完整的公司列表

历史 & 预测期
本研究报告对各个细分市场进行了分析 2018 到 2028 考虑到 2021 为基准年.

报告范围
– To analyze and forecast the market size of the global biopharmaceutical contract manufacturing market.
– To classify and forecast the global biopharmaceutical contract manufacturing market based on product, service, source, 组织规模, 地区.
– To identify drivers and challenges for the global biopharmaceutical contract manufacturing market.
– 检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global biopharmaceutical contract manufacturing market.
– To identify and analyze the profile of leading players operating in the global biopharmaceutical contract manufacturing market.

为什么选择这份报告
– Gain a reliable outlook of the global biopharmaceutical contract manufacturing market forecasts from 2022 到 2028 跨场景.
– 确定投资的增长领域.
– 通过公司简介和市场数据领先于竞争对手.
– Excel 格式的跨场景分析易用性的市场预估.
– 三个月的战略咨询和研究支持.
– 为单用户许可证提供打印验证.